Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Eyewire+ image

News from Eyewire+

Stay current with all the latest and breaking news from Eyewire+. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 128 have been published by Eyewire+ which Ground News has aggregated in the past 3 months.

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

FDA Approves Tryptyr Eye Drops for Dry Eye Disease

FDA Approves Tryptyr Eye Drops for Dry Eye Disease

50% Center coverage: 42 sources

MONDAY, June 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.See the Story

Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say - Novo Nordisk (NYSE:NVO)

Senior Citizens

Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say - Novo Nordisk (NYSE:NVO)

36% Left coverage: 28 sources

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer.See the Story

CARRA Announces Rachel Myslinski as New CEO

Olivia Chow · Washington

CARRA Announces Rachel Myslinski as New CEO

63% Center coverage: 19 sources

WASHINGTON, June 4, 2025 /PRNewswire/ -- The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has named Rachel Myslinski, MBA, as Chief Executive Officer (CEO).See the Story

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

100% Center coverage: 5 sources

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support clinical development of lead program SB-007 in Stargardt diseaseFunding will also advance a broader pipeline…Startups See the Story

FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation

100% Center coverage: 1 sources

The FDA has approved preodnisolone acetate ophthalmic suspension, USP 1%, for treating steroid-responsive ocular inflammation. Amneal Pharmaceuticals plans to launch the product in Q3...FDA · United States See the Story

Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data

Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a more convenient alternative to current injection-based treatments. Migaldendranib has a novel mechanism of action involving normalization of vascular endothelial growth factor …Maryland · Maryland Read Article

Qlaris Bio Announces Development of QLS-111-FDC

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.See the Story

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Coverage: 2 sources

NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)--Jun 9, 2025-Nashville, Tennessee · Nashville See the Story

EC Authorises Sydnexis’ Paediatric Myopia Treatment

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.Sydney, Australia · Sydney See the Story

ViGeneron Rebrands as VeonGen Therapeutics, Announces Rare Pediatric Disease Designation for VG801

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.See the Story

Best Corrected Visual Acuity - an Overview

Researchers at the National Institutes of Health (NIH) says they have identified specific brain circuits vital to visual acuity and uncovered how these circuits are disrupted by damage to retinal cells, a discovery that could reshape the future of vision restoration therapies. The research, published in The Journal of Neuroscience, suggests that effective vision repair must go beyond the retina to address the broader neural pathways responsible …National Institutes of Health · Bethesda See the Story

Breaking News Topics Related to Eyewire+